STOCK TITAN

Halozyme director Matthew L. Posard sells 5,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. director Matthew L. Posard sold 5,000 common shares on November 18, 2026 in two reported transactions: 3,400 shares at a weighted-average price of $96.1730 per share and 1,600 shares at $96.9740 per share. The sales were made under a written Rule 10b5-1 trading plan adopted on June 15, 2026.

Insider Posard Matthew L.
Role Director
Sold 5,000 shs ($482K)
Type Security Shares Price Value
Sale Common Stock F1, F2 3,400 $96.173 $327K
Sale Common Stock F1, F3 1,600 $96.974 $155K
Holdings After Transaction: Common Stock — 48,609 shares (Direct)
Footnotes (3)
  1. F1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
  2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $95.680 to $96.590. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.700 to $97.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares sold 5,000 shares Two direct-sale transactions on November 18, 2026
Shares sold (first transaction) 3,400 shares November 18, 2026
Weighted-average sale price (first transaction) $96.1730 per share 3,400-share sale on November 18, 2026
Shares sold (second transaction) 1,600 shares November 18, 2026
Weighted-average sale price (second transaction) $96.9740 per share 1,600-share sale on November 18, 2026
Rule 10b5-1 regulatory
"written trading plan adopted on June 15, 2026 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average sales price financial
"Represents a weighted average sales price per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HALO shares did Matthew L. Posard sell?

Halozyme director Matthew L. Posard sold 5,000 common shares on November 18, 2026, in two transactions: 3,400 shares and 1,600 shares.

What price ranges did Matthew L. Posard report for his HALO stock sales?

The 3,400-share sale was at prices ranging from $95.680 to $96.590 per share; the 1,600-share sale ranged from $96.700 to $97.490 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Posard Matthew L.

(Last)(First)(Middle)
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026S(1)3,400D$96.173(2)50,209D
Common Stock11/18/2026S(1)1,600D$96.974(3)48,609D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $95.680 to $96.590. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $96.700 to $97.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Remarks:
/s/ James R. Oehler, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading